July 16th 2024
A recent study found that hormone therapy use in breast cancer patients aged 65 years and older is associated with a reduced risk of Alzheimer's and related dementias.
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
4th Annual International Congress on the Future of Women’s Health™
View More
Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments
View More
Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions
View More
16th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™
May 3, 2025
View More
Aromatase inhibitor may improve outcome in premenopausal breast cancer
June 12th 2014Adjuvant therapy combining ovarian suppression with an aromatase inhibitor-a class of drugs typically only recommended for postmenopausal patients-may be more beneficial for premenopausal patients with breast cancer than tamoxifen.
Read More
Black women at higher risk of triple-negative breast cancer
May 29th 2014A new analysis of data from a nationwide hospital-based dataset shows that black women have higher odds of being diagnosed with triple-negative breast cancer-a subtype associated with poorer prognosis-than do white women, regardless of socioeconomic status (SES). The report was published in the June issue of Breast Cancer Research and Treatment.
Read More
25-year study questions value of screening mammography
February 20th 2014A new study with up to 25 years’ follow up is reopening debate about the value of screening mammography in women aged 40 to 59. Published in BMJ, the Canadian research found that 22% of women in that screening population-or 1 in every 424-had an over-diagnosed breast cancer.
Read More
Survival better with lumpectomy-not mastectomy-for early breast cancer
January 23rd 2014According to a recent observational study in JAMA Surgery, women with early-stage invasive breast cancers have higher rates of disease-specific survival when they undergo breast-conserving therapy (BCT) than women who undergo mastectomy.
Read More
Walking lowers breast cancer risk
October 10th 2013Postmenopausal women who walk at least 7 hours per week have a significantly lower risk of breast cancer than their less active counterparts. Those are the findings of a large epidemiologic study published in Cancer: Epidemiology Biomarkers & Prevention.
Read More
Does HRT raise risk of breast cancer in thin or obese women?
September 26th 2013A new registry-based study sheds light on patient factors that may influence risk of breast cancer associated with use of postmenopausal hormone replacement therapy (HRT)-including race, weight, and breast density. Findings from the report, published in The Journal of the National Cancer Institute, suggest the greatest association between HRT use and breast cancer in women with low/normal body mass index (BMI) and extremely dense breasts.
Read More
USPSTF updates guidelines on medication for breast cancer risk reduction
September 26th 2013In an update of its 2002 recommendation on use of medications for breast cancer risk reduction, the U.S. Preventive Services Task Force (USPSTF) is encouraging informed decision-making and cautioning against use of medications for prevention in women who are not at increased risk of the disease.
Read More
FDA prepares to approve Perjeta for use pre-surgery
September 19th 2013The Food and Drug Administration’s (FDA) advisory committee cleared the way for the approval of pertuzumab (Perjeta) to treat patients before they have surgery to remove their HER2-positive tumors. If approved, pertuzumab would be the first neoadjuvant drug approval for any form of cancer. The drug was already approved by the FDA for treatment of late-stage breast cancer last year.
Read More